香港联交所最新资料显示，12月23日，谊砾控股(00076)股东将股票由大湾区深港证券转入星展银行香 港，转仓市值336.72万港元，占比5.49%。 1.从2026年1月1日起，子公司将与青岛公司合作拓展青岛公司属下的高尔夫球场和天然温泉酒店等业 务。子公司将引进人工智能技术及以大健康概念融入青岛公司业务中。 2.订约双方同意青岛公司将向子公司支付100万元人民币合作管理费，签约后30天内支付10%，另外90% 于2026年12月31日前支付。双方并同意若青岛公司于2026年盈利达5000万元人民币，子公司将额外分享 青岛公司盈利中的10%，此款将于2027年1月31日前由青岛公司向子公司支付。(截至2025年11月30日止 11个月，青岛公司营业额为6500万元人民币，盈利录得2500万元人民币)。 谊砾控股12月23日发布公告，公司的全资附属公司谊砾石墨有限公司和青岛天泰文旅产业集团有限公司 于2025年12月23日签订为期三年的合作管理合约。合约主要内容为： ...

Core Viewpoint - Northeast Pharmaceutical is focusing on market trends, leveraging its two core sales segments, raw materials and formulations, to achieve significant results and ensure stable performance for the company [1] Raw Material Segment - Northeast Pharmaceutical is a key global supplier of raw materials, enhancing its international market competitiveness, particularly in the EU and Japan/Korea, with market share increasing year by year [2] - The raw material sales company demonstrated strong market capabilities in Q4, with profits exceeding planned targets for two consecutive months in October and November, particularly in November [2] - Key products such as Vitamin C and L-Carnitine exceeded sales targets, while other products like Amantadine and Piracetam also performed well, enhancing the product matrix's competitiveness [2] - The company actively participated in major industry exhibitions to connect with core customer needs and adjust market strategies based on competitor insights [2][3] Formulation Segment - Northeast Pharmaceutical's formulation products rank first in domestic sales, contributing to economic benefits and enhancing brand recognition [4] - The formulation sales company is focusing on maintaining and expanding the market competitiveness of key products, with systematic planning for products like Gut Health and Pain Relief tablets [4] - Efficient execution and collaboration among teams have led to achieving monthly performance targets, providing confidence for year-end goals [4][5] Expansion into New Fields - In Q4, Northeast Pharmaceutical made significant strides in the health sector by launching new products such as health biscuits and advancing the development of additional health-oriented snacks [6] - The company is exploring the beauty sector with functional skincare products, leveraging its pharmaceutical-grade standards in product development [6] - The company aims to optimize its health product matrix and explore comprehensive health services, creating new growth points [6]

Core Insights - The company is focusing on market trends, with its two core sales segments, raw materials and formulations, playing a significant role in stabilizing performance and achieving important results in market penetration [1][2] - The company is actively expanding in the health sector, launching new products that contribute to comprehensive health services, providing confidence and direction for future work [1][4] Raw Material Segment - The company is a key global supplier of raw materials, enhancing its international market competitiveness, particularly in the EU and Japan, with market share increasing year by year [1][2] - In Q4, the raw material sales company demonstrated strong market capabilities, exceeding profit targets in October and November, with notable performance in November [1][2] - Key products such as Vitamin C and L-Carnitine significantly outperformed sales targets, indicating a strengthening product matrix [1][2] Market Expansion and Management - The raw material sales company has actively participated in major industry exhibitions to engage with core customers and align market orders, while also monitoring industry trends and competitor dynamics [2] - Internal management has been enhanced, with a focus on accountability and improving business capabilities, leading to effective collaboration across departments [2] Formulation Segment - The company has several formulation products that rank first in domestic sales, contributing to economic benefits and enhancing brand recognition [3] - A systematic approach has been adopted to boost sales of key products, with effective execution leading to monthly performance improvements [3] New Product Development - In Q4, the company made significant strides in the health sector by launching new products such as health-oriented biscuits, while also developing additional products to meet diverse health needs [4] - The company is leveraging its experience in R&D and quality control to explore the health food sector, including functional skincare products that integrate pharmaceutical technology [4][5] Strategic Focus - The company aims to leverage its comprehensive advantages in innovation, resource allocation, and market positioning to optimize its health product matrix and explore new growth points in the health sector [5]

1.从2026年1月1日起，子公司将与青岛公司合作拓展青岛公司属下的高尔夫球场和天然温泉酒店等业 务。子公司将引进人工智能技术及以大健康概念融入青岛公司业务中。 谊砾控股(00076)发布公告，公司的全资附属公司谊砾石墨有限公司和青岛天泰文旅产业集团有限公司 于2025年12月23日签订为期三年的合作管理合约。合约主要内容为： 2.订约双方同意青岛公司将向子公司支付100万元人民币合作管理费，签约后30天内支付10%，另外90% 于2026年12月31日前支付。双方并同意若青岛公司于2026年盈利达5000万元人民币，子公司将额外分享 青岛公司盈利中的10%，此款将于2027年1月31日前由青岛公司向子公司支付。(截至2025年11月30日止 11个月，青岛公司营业额为6500万元人民币，盈利录得2500万元人民币)。 ...

2.订约双方同意青岛公司将向子公司支付100万元人民币合作管理费，签约后30天内支付10%，另外90% 于2026年12月31前支付。双方并同意若青岛公司于2026年盈利达5000万元人民币，子公司将额外分享青 岛公司盈利中的10%，此款将于2027年1月31日前由青岛公司向子公司支付。(截至2025年11月30日止11 个月，青岛公司营业额为6500万元人民币，盈利录得2500万元人民币)。 1.从2026年1月1日起，子公司将与青岛公司合作拓展青岛公司属下的高尔夫球场和天然温泉酒店等业 务。子公司将引进人工智能技术及以大健康概念融入青岛公司业务中。 格隆汇12月23日丨谊砾控股(00076.HK)发布公告，公司的全资附属公司谊砾石墨有限公司("子公司")和 青岛天泰文旅产业集团有限公司("青岛公司")于2025年12月23日签订为期三年的合作管理合约("该合 约")。合约主要内容为： ...

1.从2026年1月1日起，子公司将与青岛公司合作拓展青岛公司属下的高尔夫球场和天然温泉酒店等业 务。子公司将引进人工智能技术及以大健康概念融入青岛公司业务中。 2.订约双方同意青岛公司将向子公司支付100万元人民币合作管理费，签约后30天内支付10%，另外90% 于2026年12月31日前支付。双方并同意若青岛公司于2026年盈利达5000万元人民币，子公司将额外分享 青岛公司盈利中的10%，此款将于2027年1月31日前由青岛公司向子公司支付。(截至2025年11月30日止 11个月，青岛公司营业额为6500万元人民币，盈利录得2500万元人民币)。 智通财经APP讯，谊砾控股(00076)发布公告，公司的全资附属公司谊砾石墨有限公司和青岛天泰文旅产 业集团有限公司于2025年12月23日签订为期三年的合作管理合约。合约主要内容为： ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 ELATE HOLDINGS LIMITED 誼礫控股有限公司 （ 於香港註冊成立之有限公司） （ 股份代號： 076） 自願公告 業務發展最新情況 本公司董事會(「董事會」)欣然宣布，本公司之全資附屬公司誼礫石墨有限公司 （「子公司」）和青島天泰文旅產業集團有限公司（「青島公司」）於二零二五年 十二月二十三日簽訂為期三年之合作管理合約（「該合約」）。合約主要內容為： 1 1. 從二零二六年一月一日起，子公司將與青島公司合作拓展青島公司屬下的高 爾夫球場和天然溫泉酒店等業務。子公司將引進人工智能技術及以大健康概 念融入青島公司業務中。 2. 訂約雙方同意青島公司將向子公司支付 100 萬元人民幣合作管理費，簽約後 30 天內支付 10%，另外 90%於二零二六年十二月三十一日前支付。雙方並 同意若青島公司於二零二六年盈利達 5,000 萬元人民幣，子公司將額外分享 青島公司盈利中的 10%，此款將於二零 ...

12月20日，第四届中国营养师发展大会在珠海国际会展中心隆重启幕。作为营养健康领域的年度标杆盛会，本届大会汇聚了全国顶尖的营养专家，聚焦行业 最新动态与前沿实践，共商专业标准提升之路，共谋行业发展破局之策，为全民健康注入坚实的专业动能。 第四届中国营养师发展大会在珠海举行 健康中国的实现，既需要产业端的产品创新，也需要服务端的人才支撑。本次大会的一大亮点，便是益海嘉里金龙鱼宣布由金龙鱼慈善公益基金会捐赠150 万元设立"中国营养学会—丰益堂营养师助航基金"，以公益力量破解人才瓶颈，为健康中国筑牢人才根基。 在营养师公益基金发布仪式上，中国营养学会理事长杨月欣教授、中国营养学会常务副理事长马爱国教授、益海嘉里金龙鱼公共事务部执行总监姜元荣博士 等共同启动这一助力行业发展的公益项目。 "中国营养学会—丰益堂营养师助航基金"正式发布 人才破局，公益基金打通科学膳食落地通道 "健康中国2030"战略的深入推进，正在重塑国民健康认知与食品消费逻辑。目前，以益海嘉里金龙鱼为代表的粮油食品企业，已推出多款获得国内营养专家 认可的健康功能性产品。但产业升级的深层挑战，不仅在于生产端的研发创新，消费者对健康功能性食品的认知偏差 ...

Core Insights - The article highlights the career transition of Chen Xue, who joined Taikang in July 2023 as a Health Wealth Planner (HWP), emphasizing her commitment to the health and retirement planning sector [3][4]. Group 1: Career Transition - Chen Xue's decision to join Taikang reflects her deep consideration of professional value and a strong belief in retirement security [3]. - Her background in the banking system provided her with essential skills in asset allocation and risk management, which she now applies in her new role [3][4]. - The encounter with Taikang's health industry model was pivotal for her career shift, as it aligns with her desire to offer comprehensive and empathetic service solutions [4]. Group 2: Professional Development - The transition to HWP necessitated a comprehensive upgrade of Chen's skills, integrating her financial expertise with Taikang's high-quality, full-lifecycle health and wellness service system [4]. - Chen has evolved into a professional capable of providing a one-stop service for retirement, health, and wealth management, addressing clients' needs throughout their entire lifecycle [4]. Group 3: Vision and Mission - Chen emphasizes the importance of Taikang's ecosystem in the longevity era, which aims to create a closed loop of longevity, health, and wealth [5]. - Her professional mission is to make insurance accessible, convenient, and affordable, contributing to people's longevity, health, and wealth, while positioning Taikang as a part of their happy lives [5].

Core Viewpoint - The 2025 Southeast Modern Agriculture Expo and Flower Expo showcased the innovative products of Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd, emphasizing its commitment to integrating tradition with innovation in the health industry [1]. Group 1: Product Launches - Pien Tze Huang launched four core product series across its three strategic segments: a classic product series in the pharmaceutical sector, an Eastern skincare series in the beauty segment, and a health food series focused on food-medicine integration [1][3]. - The pharmaceutical segment introduced new products such as Renrong Anshen Pills and Xihuang Pills, targeting specific health needs and enhancing the product matrix [3]. - The beauty segment highlighted new offerings like the Jin Xian Lian series and Ren Shen series, focusing on the efficacy of traditional Chinese ingredients for skincare [3]. - The health food segment presented four new products, including a low-temperature fermented green plum wine and a green plum essence pill, both made from high-quality ingredients sourced from Fujian [4]. Group 2: Innovation and Development Strategy - Innovation is identified as the core driver for revitalizing traditional brands, with the new product launch marking a significant step towards establishing a diversified health service system [4]. - Pien Tze Huang plans to invest 270 million yuan in R&D in 2024, reflecting a 16.38% increase year-on-year, with ongoing clinical research on five traditional Chinese medicine innovations and four chemical drug innovations [4]. - The company aims to strengthen its core business while expanding its product matrix and developing a second growth curve, aligning with the "14th Five-Year Plan" and "Healthy China" strategy [5].